BACKGROUND: Primary biliary cirrhosis (PBC) is an autoimmune liver disease targeting the intrahepatic small bile ducts showing chronic non-suppurative destructive cholangitis (CNSDC). Recent studies suggest that naturally-occurring CD4+CD25high regulatory T cells (Tregs) expressing Forkhead box P3 (Foxp3) play an active role in immunological self-tolerance. AIMS: To investigate whether Foxp3+Tregs are involved in the pathogenesis of PBC. METHODS: Foxp3+Tregs was detected immunohistochemically in livers from patients with PBC (n = 27), chronic viral hepatitis (CVH) (n = 15), and normal subjects (n = 10). The distribution of Tregs in portal tracts was semi-quantitatively evaluated in each groups. Levels of Foxp3, IL-10, TGFbeta, IFNgamma and TNFalpha mRNA was evaluated in PBC (n = 15) and control livers (n = 21) using semi-quantitative reverse transcriptase-PCR. RESULTS: In PBC and CVH livers, the amounts of infiltrating Foxp3+Tregs in portal tracts were in parallel with the degree of portal inflammation irrespective of disease. The infiltration of Foxp3+Tregs into portal tracts with CNSDC in PBC was foremost in comparison with inflamed portal tracts in CVH or those without CNSDC in PBC (p<0.05). Focally, Tregs infiltrated into the biliary epithelial layer at the site of CNSDC. The level of Foxp3, IL-10 and TGFbeta mRNA expression was high in PBC compared with normal livers (p<0.05). IFNgamma and TNFalpha mRNA was high in early PBC and CVH livers. CONCLUSION: Results of this evaluation of Foxp3+Tregs do not suggest that the reduced regulatory function accounts for the development of CNSDC in PBC.
BACKGROUND:Primary biliary cirrhosis (PBC) is an autoimmune liver disease targeting the intrahepatic small bile ducts showing chronic non-suppurative destructive cholangitis (CNSDC). Recent studies suggest that naturally-occurring CD4+CD25high regulatory T cells (Tregs) expressing Forkhead box P3 (Foxp3) play an active role in immunological self-tolerance. AIMS: To investigate whether Foxp3+Tregs are involved in the pathogenesis of PBC. METHODS:Foxp3+Tregs was detected immunohistochemically in livers from patients with PBC (n = 27), chronic viral hepatitis (CVH) (n = 15), and normal subjects (n = 10). The distribution of Tregs in portal tracts was semi-quantitatively evaluated in each groups. Levels of Foxp3, IL-10, TGFbeta, IFNgamma and TNFalpha mRNA was evaluated in PBC (n = 15) and control livers (n = 21) using semi-quantitative reverse transcriptase-PCR. RESULTS: In PBC and CVH livers, the amounts of infiltrating Foxp3+Tregs in portal tracts were in parallel with the degree of portal inflammation irrespective of disease. The infiltration of Foxp3+Tregs into portal tracts with CNSDC in PBC was foremost in comparison with inflamed portal tracts in CVH or those without CNSDC in PBC (p<0.05). Focally, Tregs infiltrated into the biliary epithelial layer at the site of CNSDC. The level of Foxp3, IL-10 and TGFbeta mRNA expression was high in PBC compared with normal livers (p<0.05). IFNgamma and TNFalpha mRNA was high in early PBC and CVH livers. CONCLUSION: Results of this evaluation of Foxp3+Tregs do not suggest that the reduced regulatory function accounts for the development of CNSDC in PBC.
Authors: Hideaki Sugiyama; Rolland Gyulai; Eiko Toichi; Edina Garaczi; Shinji Shimada; Seth R Stevens; Thomas S McCormick; Kevin D Cooper Journal: J Immunol Date: 2005-01-01 Impact factor: 5.422
Authors: S Shimoda; J Van de Water; A Ansari; M Nakamura; H Ishibashi; R L Coppel; J Lake; E B Keeffe; T E Roche; M E Gershwin Journal: J Clin Invest Date: 1998-11-15 Impact factor: 14.808
Authors: Kalliopi Zachou; Eirini I Rigopoulou; Aikaterini Tsikrikoni; Michael G Alexandrakis; Freda Passam; Despina S Kyriakou; Nicolaos E Stathakis; Georgios N Dalekos Journal: J Autoimmun Date: 2005-10-20 Impact factor: 7.094
Authors: Sarah E Allan; Laura Passerini; Rosa Bacchetta; Natasha Crellin; Minyue Dai; Paul C Orban; Steven F Ziegler; Maria Grazia Roncarolo; Megan K Levings Journal: J Clin Invest Date: 2005-10-06 Impact factor: 14.808
Authors: Andrea T Borchers; Shinji Shimoda; Christopher Bowlus; Carl L Keen; M Eric Gershwin Journal: Semin Immunopathol Date: 2009-06-17 Impact factor: 9.623